QYQingyu Yang

Qingyu Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qingyu Yang has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Xi Zhou

    State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, CAS, Wuhan, China

    3 shared publications
  • Chaolin Huang

    Wuhan Jinyintan Hospital

    2 shared publications
  • Dihan Zhou

    Wuhan Institute of Virology, Chinese Academy of Sciences (CAS)

    2 shared publications
  • Dingyu Zhang

    Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Key Laboratory of Anesthesiology and Resuscitation (Huazhong University of Science and Technology), Ministry of Education, China

    2 shared publications
  • Ejuan Zhang

    Wuhan Institute of Virology, Chinese Academy of Sciences (CAS)

    2 shared publications
  • Huimin Yan

    Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China

    2 shared publications

Latest Publications

  • Open Access

    Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19

    by Yang Han, Peipei Liu, Yang Qiu, Jie Zhou, Ying Liu, Xujuan Hu, Qingyu Yang, Rui Huang, Xinyue Wen, Hao Song, et al.

    The coronavirus disease 19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the worst public health crisis in a century. However, knowledge about the dynamics of antibody responses in patients with COVID-19 is still poorly understood. In this study, we performed a serological study with serum specimens collected at the acute and the convalescent phases from 104 patients with severe COVID-19 who were part of the first wave of COVID-19 cases in Wuhan, China. Our findings revealed that neutralizing antibodies to SARS-CoV-2 are persistent for at least 6 months in patients with severe COVID-19, despite that IgG levels against the receptor binding domain (RBD) and nucleocapsid protein (N) IgG declined from the acute to the convalescent phase. Moreover, we demonstrate that the level of RBD-IgG is capable of correlating with SARS-CoV-2–neutralizing activities in COVID-19 serum. In summary, our findings identify the magnitude, functionality, and longevity of antibody responses in patients with COVID-19, which sheds light on the humoral immune response to COVID-19 and would be beneficial for developing vaccines.


  • Open Access

    Broad phenotypic alterations and potential dysfunctions of lymphocytes in COVID-19 recovered individuals

    by Jingyi Yang, Maohua Zhong, Ejuan Zhang, Ke Hong, Qingyu Yang, Dihan Zhou, Jianbo Xia, Yao-Qing Chen, Mingbo Sun, Bali Zhao, et al.

    Summary: Background: Lymphopenia is a typical symptom in the COVID-19 patients. While millions of patients are clinical recovered, little is known about the immune status of lymphocytes in these individuals. Methods: A clinical recovered cohort (CR) of 55 COVID-19 individuals (discharged from hospital 4 to 11 weeks), and 55 age and sex matched healthy donors cohort (HD) were recruited. Detailed analysis on phenotype of the lymphocytes in peripheral blood mononuclear cells (PBMCs) was performed by flow cytometry. Findings: Compared with cohort HD, the CD8 + T cells in cohort CR had higher Teff and Tem, but lower Tc1 (IFN-γ + ), Tc2 (IL-4 + ) and Tc17 (IL-17A + ) frequencies. The CD4 + T cells of CR had decreased frequency, especially on the Tcm subset. Moreover, CD4 + T cells of CR expressed lower PD-1 and had lower frequencies of Th1 (IFN-γ + ), Th2 (IL-4 + ), Th17 (IL-17A + ) as well as circulating Tfh (CXCR5 + PD-1 + ). Accordingly, isotype-switched memory B cell (IgM - CD20 hi ) in CR had significantly lower proportion in B cells, though level of activation marker CD71 elevated. For CD3 - HLA-DR lo lymphocytes of CR, besides levels of IFN-γ, Granzyme B and T-bet were lower, the correlation between T-bet and IFN-γ became irrelevant. In addition, taken into account of discharged days, all the lowered function associated phenotypes showed no recovery tendency within whole observation period. Interpretation: The CR COVID-19 individuals still showed remarkable phenotypic alterations in lymphocytes after clinical recovery 4 to 11 weeks. This suggests SARS-CoV-2 infection imprints profoundly on lymphocytes and results in long-lasting potential dysfunctions. Funding: Kunming Science and Technology Department (2020-1-N-037)


  • Open Access

    Impaired T cell functions along with elevated activated Tregs at the early stage of asymptomatic SARS-CoV-2 infection

    by Jingyi Yang, Ejuan Zhang, Maohua Zhong, Qingyu Yang, Ke Hong, Ting Shu, Dihan Zhou, Jie Xiang, Jianbo Xia, Xi Zhou, et al.

    Summary: Background: Limited data are available on the T cell responses for the asymptomatic SARS-CoV-2 infection case. Methods: An imported SARS-CoV-2 infection case in Wuhan was admitted in hospital for quarantine and observation. The T cell responses were followed up by flow cytometry analysis of the peripheral blood nonnuclear cells (PBMCs) at days 7, 13, 22, and 28 after admission. Findings: We found the imported SARS-CoV-2 infection in Wuhan is an asymptomatic case. His T cell differentiation, proliferation and activation matched the classical kinetics of T cell responses induced by viral infection, but the activation maintained at a relatively low level. Function analysis indicated frequencies of IFN-γ producing CD4 + and CD8 + T cells were notably lower than that of the healthy controls (HC) at day 7, and then rebound gradually. But IFN-γ + CD8 + T cells were detained at a significant lower level even at day 28, when the SARS-CoV-2 virus had already become undetectable for 3 weeks. Moreover, percentage of IL-17 producing CD4 + T cells was also detained constantly at a much lower level compared to HC. At day 7, although percentage of Tregs was in normal range, the frequency of activated Treg (aTreg) was remarkably as high as 4·4-fold of that in HC. Interpretation: The T cell activation in the asymptomatic SARS-CoV-2 infection experienced a significant suppression and presented impairment of Th1/Th17 and CD8 + T cell functions. Early elevation of the aTregs might play role in the activation and function of T cells in the asymptomatic SARS-CoV-2 infection.


  • Open Access

    Cullin1 represses systematic inflammasome activation by binding and catalyzing NLRP3 ubiquitination

    by Pin Wan, Qi Zhang, Weiyong Liu, Yaling Jia, Tianci Wang, Wenbiao Wang, Pan Pan, Ge Yang, Qi Xiang, Siyu Huang, et al.

    Activation of the NLRP3 inflammasome is a key process of host immune response, the first line of defense against cellular stresses and pathogen infections. However, excessive inflammasome activation damages the hosts, and thus it must be precisely controlled. The mechanism underlying the repression of systematic inflammasome activation remains largely unknown. This study reveals that CUL1, a key component of the SCF E3 ligase, plays a critical role in regulation of the inflammasome. CUL1 suppresses the inflammasome activation in HEK293T cells, inhibits endogenous NLRP3 in macrophages, and represses inflammatory responses in C57BL/6 mice. Under normal physiological conditions, CUL1 interacts with NLRP3 to disrupt the inflammasome assembly, and catalyzes NLRP3 ubiquitination to repress the inflammasome activation. In response to inflammatory stimuli, CUL1 disassociates from NLRP3 to release the repression of NLRP3 inflammasome activation. This work reveals a distinct mechanism underlying the repression of inflammasome activation under physiological conditions and the induction of inflammasome activation in response to inflammatory stimuli, and thus provides insights into the prevention and treatment of infectious and inflammatory diseases.


  • Open Access

    Antiviral effects against EV71 of pimprinine and its derivatives isolated from Streptomyces sp

    by Yanhong Wei, Wei Fang, Zhongyi Wan, Kaimei Wang, Qingyu Yang, Xiaofeng Cai, Liqiao Shi, Ziwen Yang

    The pimprinine family of compounds represent very important and promising microbial metabolites for drug discovery. However, their ability in inhibiting viral infections has not yet been tested. The antiviral activity of the pimprinine family of compounds was evaluated by determining the cytopathic effect (CPE), cell viability or plaque-forming unit (PFU), and virus yield. The mechanism of action against EV71 was determined from the virucidal activity, and effective stage and time-of-addition assays. The effects on EV71 replication were evaluated further by determining viral RNA synthesis, protein expression and cells apoptosis using the SYBR Green assays, immunofluorescence assays and flow cytometric assays, respectively. Pimprinethine, WS-30581 A and WS-30581 B inhibited EV71-induced CPE, reduced progeny EV71 yields, as well as prevented EV71-induced apoptosis in human rhabdomyosarcoma (RD) cells. These compounds were found to target the early stages of the EV71 replication in cells including viral RNA replication and protein synthesis. They also showed antiviral activity against ADV-7, and were slightly active against CVB3, HSV-1 and H1N1 with a few exceptions. Pimprinine was slightly active or inactive against all the viruses tested. The mechanisms by which these compounds act against the viruses tested may be similar to that demonstrated for EV71. The data described herein demonstrate that the pimprinine family of compounds are inhibitors effective against the replication of EV71 and ADV-7, so they might be feasible therapeutic agents for the treatment of viral infections.